Hannoversche Kinderheilanstalt

At the Hannoversche Kinderheilanstalt, researchers are evaluating new approaches to lower cholesterol in children with genetic lipid disorders. The focus is on improving low‑density lipoprotein cholesterol (LDL‑C) outcomes for youngsters with heterozygous familial hypercholesterolemia (HeFH) using innovative agents.

• Assessing the efficacy of novel lipid‑lowering therapies in pediatric patients
• Understanding long‑term safety of cholesterol‑targeted drugs
• Integrating genetic screening into cardiovascular risk management

The site’s multidisciplinary team of four investigators is leading these studies, contributing to better heart health for children at risk.

Clinical work at the Hanover hospital includes trials that protect the most vulnerable newborns and children with growth challenges. One study examines automated oxygen delivery for extremely preterm infants, while another tests growth‑hormone strategies for conditions such as Turner syndrome and short stature due to SHOX deficiency.

• Closed‑loop ventilation to reduce oxygen‑related complications in preterm babies
• Evaluating weekly long‑acting growth hormone versus daily therapy
• Genetic assessment and tailored treatment for growth disorders

These projects aim to improve survival, developmental outcomes, and stature growth for children born with complex neonatal and hereditary conditions.

A core research theme at the site is early intervention in type 1 diabetes. Multiple trials investigate immunomodulatory drugs such as teplizumab and baricitinib to preserve beta‑cell function and delay disease progression in children and young adults.

• Testing immune‑targeted therapies to maintain insulin production
• Studying safety and tolerability of novel agents in newly diagnosed patients
• Identifying biomarkers that predict response to treatment

The collaborative effort seeks to change the course of autoimmune diabetes and improve quality of life for affected families.

While primarily focused on endocrine disorders, the institution also addresses skeletal health through growth‑related research. Studies on long‑acting growth hormone evaluate its impact on bone development and overall musculoskeletal growth in children with growth failure.

• Measuring bone density changes with weekly hormone therapy
• Comparing efficacy of daily versus weekly growth‑hormone regimens
• Assessing functional outcomes such as height velocity and joint health

These investigations support children whose musculoskeletal growth is limited by hormonal or genetic factors.

The department conducts several trials targeting metabolic balance in youth. Research includes preserving beta‑cell function in type 1 diabetes and exploring weight‑maintenance strategies with semaglutide for adolescents who have achieved initial obesity reduction.

• Long‑term monitoring of insulin secretion in diabetic children
• Evaluating weight‑maintenance outcomes after pharmacologic intervention
• Studying metabolic biomarkers linked to disease progression

By addressing both glucose regulation and body‑weight control, the trials aim to foster healthier metabolic trajectories for young patients.

Underlying many of the site’s studies is a focus on fundamental metabolic processes. Trials assess how treatments influence glucose metabolism, C‑peptide response, and overall energy balance in children with diabetes and metabolic disorders.

• Analyzing mixed‑meal tolerance test results to gauge pancreatic function
• Investigating metabolic effects of novel oral agents on insulin secretion
• Linking metabolic changes to clinical outcomes in pediatric populations

This work enhances understanding of pediatric metabolism and supports the development of therapies that target core physiological pathways.